-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III

Symposia: Aggressive Lymphomas: Prospective Therapeutic Trials Program: Oral and Poster Abstracts
Type: Poster
Monday, December 11, 2023: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)

Joost S.P Vermaat, MD, PhD, MSc1, Joshua Brody, MD2*, Juraj Ďuraš, MD3*, Yasmin H. Karimi, MD4, Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc5, Justin M. Darrah, MD6*, Gerardo Musuraca, MD, PhD7*, Franck Morschhauser, MD, PhD8*, Daniela Hoehn, MD, PhD9*, Ali Rana, MD, PhD9*, Yaou Song, MS9*, Pegah Jafarinasabian, MD, PhD10* and David Belada, MD11*

1Leiden University Medical Center, Leiden, Netherlands
2Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Hemato-Oncology, University Hospital and Faculty of Medicine, Ostrava, CZE
4Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
5Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia
6Cedars-Sinai Medical Center, Los Angeles, CA
7IRCCS Istituto Romagnolo per lo studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
8University of Lille, CHU Lille, Lille, France
9Genmab, Plainsboro, NJ
10AbbVie, North Chicago, IL
114th Department of Internal Medicine - Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

Yuqin Song1, JUN MA2*, Yan Xie3*, Huilai Zhang, MD4*, Zhigang Peng5*, Yuerong Shuang6*, Fei Li7*, Yufu Li8*, Haiyan Yang9*, Xiuhua Sun10*, Liqun Zou11*, Yunhong Huang12*, Weili Zhao13*, Wenrong Huang14, Hui Zhou15*, Mingying Liu16*, Weiwei Wang16*, Jing Xu16*, Yajie Wang16* and Jun Zhu, MD17*

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China
2Department of Hematology & Oncology, Harbin Institute of Hematology & Oncology, Harbin, China
3Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Minis-try of Education), Peking University Cancer Hospital & Institute, Beijing, China
4Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
5The First Affiliated Hospital of Guangxi Medical University, Nanning, China
6Jiangxi Cancer Hospital, Nanchang, China
7The First Affiliated Hospital of Nanchang University, Nanchang, China
8Henan Cancer Hospital, Zhengzhou, China
9Zhejiang Cancer Hospital, Hangzhou, China
10The Second Hospital of Dalian Medical University, Dalian, China
11West China Hospital of Sichuan University, Chengdu, China
12The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
13State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China
15Hunan Cancer Hospital, Changsha, China
16Shanghai Junshi Biosciences, Shanghai, China
17Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China

Marc Hoffmann, MD1, Javier L. Munoz2, Jason Westin, MD3, Theodoros Vassilakopoulos, PhD4*, Alejandro Martin Garcia-Sancho, MD5*, Antonio Rueda Dominguez, MD6*, Wojciech Jurczak, MD, PhD7, Su-Peng Yeh, MD8*, Maria Bouzani9*, Argyrios Gkasiamis, MD10, Mark Kaplan11*, Arpankumar Patel11*, Floriane Boucaud10*, Ju Li11* and Grzegorz S. Nowakowski, MD12

1The University of Kansas Medical Center, Kansas City, KS
2Department of Hematology, Mayo Clinic, Phoenix, AZ
3Department of Lymphoma-Myeloma, MD Anderson Cancer Center, Houston, TX
4Department of Hematology and Bone Marrow Transplantation, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
5Hospital Universitario de Salamanca, Salamanca, Spain
6Regional and Virgen de la Victoria University Hospitals, Málaga, Spain
7Dpt of Clinical Oncology, MSC National Research Institute of Oncology, Kraków, Poland
8Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
9Department of Hematology and Lymphoma, Evangelismos General Hospital, Athens, Greece
10Bristol Myers Squibb, Boudry, Switzerland
11Bristol Myers Squibb, Princeton, NJ
12Department of Internal Medicine, Mayo Clinic, Rochester, MN

Martin Hutchings, MD PhD1*, Abraham Avigdor, MD2, Anna Maria Sureda Balari, MD, PhD3, Maria José Terol, MD, PhD4*, Francesc Bosch, MD PhD5*, Paolo Corradini, MD6, Thomas S. Larsen7*, Antonio Rueda Dominguez, MD8*, Alan Skarbnik, MD9, Judit Mészáros Joergensen, MD, PhD10*, David Lavie11*, Ronit Gurion, MD12*, Pier Luigi Zinzani, MD, PhD13, Antonio Pinto, MD14*, Raul Cordoba, MD, PhD15, Alessia Bottos, PhD16*, Donghang Li, PhD17*, James Relf, MD18*, Audrey Filézac De L'Étang, PhD16*, Gila Sellam, PhD16* and Giuseppe Gritti19*

1Rigshospitalet, Copenhagen, Denmark
2Sheba Medical Center, Ramat Gan and Tel Aviv University, Tel Aviv, Israel
3Universitat de Barcelona, Barcelona, Spain
4Hospital Clínico Universitario INCLIVA, University of Valencia, Valencia, Spain
5University Hospital Vall d'Hebron, Barcelona, Spain
6Hematology, University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
7Odense University Hospital, Odense, Denmark
8Regional and Virgen de la Victoria University Hospitals, Málaga, Spain
9Novant Health Cancer Institute, Lymphoma and CLL Program, Charlotte, NC
10Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
11Hadassah Medical Center, Jerusalem, Israel
12Rabin Medical Center, Petach Tikva and Tel Aviv University, Tel Aviv, Israel
13University of Bologna, Bologna, Italy
14National Cancer Institute Fondazione G. Pascale IRCCS, Naples, Italy
15Fundación Jiménez Díaz University Hospital, Madrid, Spain
16F. Hoffmann-La Roche Ltd, Basel, Switzerland
17F. Hoffmann-La Roche Ltd, Shanghai, China
18Roche Products Ltd, Welwyn Garden City, United Kingdom
19Department of Oncology-Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

Jennifer L. Crombie, MD1*, Matthew Matasar, MD, MS2, Max S. Topp, MD3*, John N. Allan, MD2, Jeffrey A. Barnes4*, Jon E. Arnason, MD5, Jean-Marie Michot6*, Neta Goldschmidt7*, Susan M. O'Brien8, Uri Abadi, MD9,10*, Irit Avivi Mazza, MD11*, Jessica Cai12*, Dina M. Flink12, Min Zhu12*, Jurriaan Brouwer-Visser12*, Hesham Mohamed12, Aafia Chaudhry12, Srikanth Ambati12* and Steve M Ansell13

1Dana Farber Cancer Institute, Boston, MA
2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
3Universitätsklinikum Würzburg, Würzburg, Germany
4Massachusetts General Hospital Cancer Center, Boston, MA
5Beth Israel Deaconess Medical Center, Boston, MA
6Gustave Roussy Cancer Campus, Villejuif, France
7Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
8Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA
9Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
10Hematology Institute, Meir Medical Center, Kfar Saba, Israel
11Ichilov University Hospital, Tel-Aviv, Israel
12Regeneron Pharmaceuticals, Inc., Tarrytown, NY
13Mayo Clinic, Rochester, MN

Oluwatobi Odetola, MD1, Shuo Ma, MD, PhD2, Jane N. Winter, MD2, Barbara Pro, MD2, Ishan Roy, MD, PhD3, Ping Xie, MD, PhD4*, Bin Zhang, MD, PhD4*, George Koulogeorgas5*, Xinlei Mi, PhD6*, Robert Bayer, MD7*, Robert Eisner, DO7, Valerie Nelson, MD7*, Habib Shaikh, DO7*, Dean Tsarwhas, MD7*, Faisal Saghir, MD7*, Parameswaran Venugopal, MD8, Leo I. Gordon, MD2 and Reem Karmali, MD, MSc9

1Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Maywood, IL
2Department of Medicine, Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL
3Shirley Ryan Ability Lab, Chicago, IL
4Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL
5Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
6Department of Preventative Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
7Feinberg School of Medicine, Northwestern University, Chicago, IL
8Rush University Medical Center, Chicago, IL
9Northwestern University, Chicago, IL

Alexey Danilov, MD1, Michael T. Tees, MD2, Krish Patel3*, William G. Wierda, MD, PhD4, Manish Patel, MD5*, Ian W. Flinn, MD, PhD6, Tahir Latif7, Weiyun Ai8, Meghan C. Thompson, MD9, Michael L. Wang, MD10, Clare Sun, MD11, Deborah M. Stephens, DO12, Michael Thirman13, Melissa Gessner14*, Johannes Wolff14*, Amanda Schwab14*, May Tan14*, Daniel Chan14*, Erin Meredith14* and Adrian Wiestner, MD15

1Department of Hematology and HCT, City of Hope National Medical Center, La Canada Flintridge, CA
2The Colorado Blood Cancer Institute a part of Sarah Cannon Cancer Institute at Presbyterian/St Luke's Medical Center, Denver, CO
3Swedish Cancer Institute, Seattle, WA
4Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
5Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL
6Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN
7University of Cincinnati Medical Center, Cincinnati, OH
8University of California San Francisco, San Francisco, CA
9Memorial Sloan Kettering Cancer Center, New York, NY
10The University of Texas MD Anderson Cancer Center, Houston, TX
11National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
12Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
13Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
14Nurix Therapeutics, Inc., San Francisco, CA
15Hematology Branch, National Heart, Lung, and Blood Institute, NIH, NHLBI, Bethesda, MD

Tomomi Toubai, MD, PhD1, Junya Kuroda, MD, PhD2, Youko Suehiro, MD, PhD3*, Yuko Mishima, PhD4*, Kazutaka Sunami, MD, PhD5, Koji Kato, M.D., Ph.D.6*, Nobuhiko Uoshima, MD, PhD7*, Takahiro Kumode, MD, PhD8*, Ai Ota, BSc9*, Kaori Mitsuki, MS10*, Daisuke Yokota, MS11*, Yuri Sano, MD, PhD12 and Yasuhito Terui, MD, PhD13*

1Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University, Yamagata, Japan
2Division of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan
3Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
4Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, TKY, Japan
5Department of Hematology, National Hospital Organization, Okayama Medical Center, Okayama, Japan
6Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan
7Japanese Red Cross, Kyoto Daini Hospital, Kyoto, JPN
8Kindai University, Osakasayama, JPN
9Otsuka Pharmaceutical Co.,Ltd., Osaka, OSA, Japan
10Otsuka Pharmaceutical Co.,Ltd., Minato-Ku, TKY, Japan
11Otsuka Pharmaceutical Co.,Ltd., Osaka, Japan
12Otsuka Pharmaceutical Co.,Ltd., Minato-ku, TKY, Japan
13Department of Hematology, Saitama Medical University Hospital, Iruma, Japan

Yuqin Song, MD1, Keshu Zhou, MD2*, Hongmei Jing, MD3, Jianqiu Wu, PhD4*, Haiyan Yang5*, Yu Bai6*, Ke Fang6*, Ziyi Liu6*, Jun Zhu, PhD7 and Chan Y. Cheah, MBBS, FRACP, FRCPA, DMSc8

1Peking University Cancer Hospital and Institute, Beijing, China
2Department of Hematology, Henan Cancer Hospital, Zhengzhou, China
3Department of Hematology, Peking University Third Hospital, Beijing, China
4Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China
5Zhejiang Cancer Hospital, Hangzhou, China
6Dizal Pharmaceutical, Shanghai, China
7Peking University Cancer Hospital, Beijing, China
8Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

Dustin McCurry, MD1, Jason Westin, MD2, Lei Feng, MS3*, Sairah Ahmed, MD2, Ranjit Nair, MD4, Raphael Eric Steiner, MD5, Lauren Wynn6*, Jennifer Thomas7*, Ly Huynh Dsouza, PA-C6*, Felipe Samaniego, MD8*, Sattva S. Neelapu, MD2 and Loretta J. Nastoupil, MD2

1The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
3Biostatistics, UT MD Anderson Cancer Center, Houston, TX
4Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston
6Lymphoma/Myeloma, UT MD Anderson Cancer Center, Houston, TX
7UT MD Anderson Cancer Center, Houston, TX
8M.D. Anderson Cancer Center, Houston, TX

Henry Ddugnu, MD, PhD1*, Kelvin Mubiru, MS2*, Scott V Adams, PhD3*, Jacqueline Asea, MSN2*, Joyce Kambugu, MBChB, MMED1*, Rosemary Namagembe, BSN2*, Prossy Namuli, BSN2*, Jackson Orem, MBChB, PhD1*, Camille Puronen, MD, MPH4, Thomas S. Uldrick, MD, MS3*, Edus H Warren, MD, PhD5,6 and Manoj P Menon, MD5,6*

1Uganda Cancer Institute, Kampala, Uganda
2Hutchinson Center Research Institute of Uganda., Kampala, Uganda
3Fred Hutchinson Cancer Center, Seattle
4University of Washington, Seattle
5Fred Hutchinson Cancer Center, Seattle, WA
6Division of Hematology and Oncology, University of Washington, Seattle, WA

Jia Jin1*, Yalan Wang2*, Xi Wang2*, Yonghong Tang3*, Shan Zeng3*, Juan Du4 and Junning Cao5

1Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, AL, China
2Department of Lymphoma, Baotou Tumor Hospital, Baotou, Inner Mongolia, China
3Department of Internal Oncology, Xiangya Hospital of Central South University, Changsha, Hunan, China
4Department of Lymphoma, Shanghai Changzheng Hospital, Shanghai, China
5Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai, China

Ningjing Lin1*, Xiuhua Sun2*, Hui Zhou3*, Liqun Zou, MD, PhD4*, Keshu Zhou, MD5*, Lihong Liu6*, Haiyan Yang7, Kai HU8*, Qingqing Cai9*, Yao Liu10*, Jie Jin, MD11, Liling Zhang12*, Wenyu Li13*, Ye Guo14*, Wei Yang15*, Feng Luo16*, Yanyan Li16*, Mengqi Zhang16*, Feinan Lu16*, Yuqin Song17* and Jun Zhu, PhD18

1Department of Lymphatic Oncology, Beijing Cancer Hospital, Beijing, China
2The Second Hospital of Dalian Medical University, Dalian, China
3Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
4West China Hospital of Sichuan University, Chengdu, China
5Department of Hematology, Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
6The Fourth Hospital of Hebei Medical University, Hebei, China
7Department of Lymphatic Oncology, Zhejiang Cancer Hospital, Hangzhou, China
8Department of Adult Lymphoma, Beijing Boren Hospital, Beijing, China
9Sun Yat-Sen University Cancer Cente, Guangzhou, China
10Chongqing University Cancer Hospital, Chongqing, China
11Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
12Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
13Guangdong Provincial People's Hospital, Guangzhou, China
14Shanghai East Hospital, Shanghai, China
15Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
16Overland Pharmaceuticals, Shanghai, China
17Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China
18Peking University Cancer Hospital, Beijing, China

Qingqing Cai, PhD1*, Yi Xia, M.D, PhD1*, Liang Wang, M.D, PhD2*, Huiqiang Huang, MD, PhD1, Jinni Wang, MSc1*, Jun Cai, M.D, PhD1* and Xiaopeng Tian, M.D, PhD1*

1Sun Yat-Sen University Cancer Center, Guangzhou, China
2Beijing Tongren Hospital, Capital Medical University, Beijing, China

Thomas M. Habermann, MD1, Betsy LaPlant, MS2*, Ivana Micallef, MD1*, Heidi Diann Finnes, PharmD3*, Jill Schimke, M.S.1*, Robin Klebig, MSN, CNP1*, Nikki Hanley4*, Rebecca L. King, MD5, Thomas E. Witzig, MD1 and Svetomir Markovic, MD, PhD6*

1Mayo Clinic, Rochester, MN
2Mayo Clinic, Rochester, Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN
3Department of Pharmacology, Mayo Clinic, Rochester, MN
4Mayo Cancer Center, Hematology, Mayo Clinic, Rochester, MN
5Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
6Department of Medical Oncology, Mayo Clinic, Rochester, MN

Noriko Fukuhara1, Yoshitaka Narita, MD, PhD2*, Motoo Nagane, MD, PhD3*, Kazuhiko Mishima, MD, PhD4*, Yasuhito Terui, MD, PhD5*, Yoshiki Arakawa, MD, PhD6*, Hajime Yonezawa, MD, PhD7*, Katsunori Asai, MD, PhD8*, Kazuhiko Sugiyama, MD, PhD9*, Naoki Shinojima, MD, PhD10*, Arata Aoi11* and Ryo Nishikawa, MD, PhD12*

1Department of Hematology and Rheumatology, Tohoku University School of Medicine, Sendai, Japan
2Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, JPN
3Department of Neurosurgery, Kyorin University Faculty of Medicine, Mitaka, TKY, JPN
4Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, Japan
5Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
6Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
7Department of Neurosurgery, Kagoshima University Hospital, Kagoshima, Japan
8Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan
9Department of Clinical Oncology & Neuro-oncology Program, Hiroshima University Hospital, Hiroshima, Japan
10Department of Neurosurgery, Kumamoto University Hospital, Kumamoto, Japan
11Department of Clinical Development, Ono Pharmaceutical Co., LTD., Osaka, Japan
12Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, JPN

Emma Searle1*, Francesco Forconi2*, Kim Linton, MD, PhD3*, Alexey Danilov, MD4, Pam McKay5*, David Lewis, MBChB, PHD6*, Dima El-Sharkawi, MBBS, FRCPath, PhD7*, Mary Gleeson8*, John Riches9*, Sarah G. Injac10*, Ted Shih10*, Srinand Nandakumar10*, May Tan10*, Ganesh Cherala10*, Erin Meredith10* and Graham P. Collins, MBBS, DPhil11

1The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom
2School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom
3The Christie Hospital and Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, GBR
4Department of Hematology and HCT, City of Hope National Medical Center, La Canada Flintridge, CA
5Haematology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
6Derriford Hospital, Plymouth, United Kingdom
7The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
8Sarah Cannon Research Institute and Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
9Barts Cancer Institute, London, United Kingdom
10Nurix Therapeutics, Inc., San Francisco, CA
11Oxford University Hospitals, Oxford, United Kingdom

Alessia Ripamonti, MD1*, Andrea Aroldi, MD2*, Federica Cocito, MD2*, Luca Guerra, MD3,4*, Lavinia Monaco, MD4*, Bianca Maria Granelli, MD3*, Lara Mussolin, PhD5* and Carlo Gambacorti-Passerini, MD2,3

1Department of Medicine and Surgery, University Milano-Bicocca, Alzate Brianza, Italy
2Hematology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
3Department of Medicine and Surgery, University Milano-Bicocca, Monza, Italy
4Nuclear Medicine Division, IRCCS San Gerardo dei Tintori, Monza, Italy
5Pediatric Hematology-Oncology, University of Padua, Padua, Italy

N. Nora Bennani, MD1, Pamela Atherton1*, Kimberly O Steinert1*, Lisa M. Rimsza, MD2, Aung M. Tun, MD3, Marc Hoffmann, MD4, Mayur S. Narkhede, MBBS5, Rakhee Vaidya, MD6*, Rabih Said7*, Geoffrey I Shapiro, MD8*, Brian A Costello, MD9*, Stephen M Ansell, MD, PhD10 and Grzegorz S. Nowakowski, MD10

1Mayo Clinic, Rochester, MN
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ
3Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas, Westwood, KS
4The University of Kansas Medical Center, Kansas City, KS
5Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL
6Wake Forest, Winston-Salem, NC
7Investigational Drug Branch, CTEP, NCI, Rockville, MD
8Dana-Farber Cancer Institute, Boston
9Medical Oncology, Mayo Clinic, Rochester, MN
10Division of Hematology, Mayo Clinic, Rochester, MN

*signifies non-member of ASH